- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
HC Wainwright Boosts CG Oncology's FY2029 Earnings Forecast
Analysts see strong growth potential for the biotech firm's cancer treatments.
Apr. 8, 2026 at 12:37pm
Got story updates? Submit your updates here. ›
HC Wainwright, a leading investment research firm, has increased its earnings forecast for CG Oncology, Inc. (NASDAQ:CGON) in fiscal year 2029. The firm's analyst A. Maldonado now expects the biopharmaceutical company to earn $3.12 per share, up from the previous estimate of $2.79 per share.
Why it matters
The revised forecast reflects growing optimism around CG Oncology's pipeline of innovative cancer therapies, which are currently in various stages of clinical development. Positive updates on the company's progress could drive further stock price appreciation and investor interest.
The details
In a research note, HC Wainwright maintained its "Buy" rating on CG Oncology and set a price target of $100 per share. The consensus estimate for the company's current full-year earnings is ($1.31) per share. HC Wainwright also issued an estimate of $6.06 EPS for CG Oncology's fiscal year 2030.
- The research note was issued on Tuesday, April 7, 2026.
The players
HC Wainwright
A leading investment research firm that covers CG Oncology and has increased its earnings forecast for the company.
A. Maldonado
The HC Wainwright analyst who revised the FY2029 earnings estimate for CG Oncology.
CG Oncology, Inc.
A clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for the treatment of solid tumor cancers.
What they’re saying
“HC Wainwright analyst A. Maldonado now anticipates that the company will earn $3.12 per share for the year, up from their previous forecast of $2.79.”
— A. Maldonado, Analyst
What’s next
Investors will be closely watching for any further updates on CG Oncology's clinical pipeline and potential regulatory milestones, which could drive additional revisions to the company's earnings forecasts.
The takeaway
The increased earnings forecast from a respected research firm like HC Wainwright suggests growing confidence in CG Oncology's ability to develop effective cancer treatments and deliver strong financial performance in the coming years.
